Feasibility of discontinuing immunosuppression in children with idiopathic nephrotic syndrome
Authors:
- 25 January 2024
- journal article
- research article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 39 (6) , 1825-1835
Abstract
Background Despite adverse events associated with the long-term use of immunosuppressants, their long-term discontinuation remains challenging in children with idiopathic nephrotic syndrome. Relapse and resumption of immunosuppressants after discontinuation and associated risk factors were analyzed. Methods This single-center retrospective cohort study included children with frequently relapsing/steroid-dependent nephrotic syndrome (FRNS/SDNS) or steroid-resistant nephrotic syndrome (SRNS) who initiated immunosuppressant treatment between 2010 and 2020. Patients treated with immunosuppressants for less than two years, those with genetic SRNS, and those with continuation of immunosuppressants were excluded. Results Sixty-eight patients with FRNS/SDNS or SRNS discontinued immunosuppressants. Discontinuation of immunosuppressants was more frequently tried in patients with less relapse on initial immunosuppressants and less rituximab administration. Of 68 patients who discontinued immunosuppressants, 45 (66%) relapsed and 31 (46%) resumed immunosuppressants with a median follow-up of 39.8 months (IQR 24.6–71.2 months) after discontinuation. The relapse-free survival rates were 40.0%, 35.3%, and 35.3% in 1, 2, and 3 years from discontinuation of immunosuppressants, respectively. Relapse on initial immunosuppressants (HR 2.038, 95%CI 1.006–4.128, P = 0.048) and the relapse-free interval before discontinuation of immunosuppressants (HR 0.971, 95%CI 0.944–0.998, P = 0.037) were significant risk factors associated with relapse after the discontinuation of immunosuppressants, adjusting for sex, age at immunosuppressant treatment initiation, SRNS, and rituximab use. Conclusions Long-term discontinuation of immunosuppressants can be feasible in patients without a relapse on initial immunosuppressants, those with longer relapse-free interval before discontinuation of immunosuppressants, and those without a relapse for one year after discontinuation of immunosuppressants. Trial registration Not applicable. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary informationKeywords
All Related Versions
This publication has 19 references indexed in Scilit:
- Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trialPediatric Nephrology, 2014
- Lymphoma risk in systemic lupus: effects of disease activity versus treatmentAnnals of the Rheumatic Diseases, 2014
- Two-Year Follow-Up of a Prospective Clinical Trial of Cyclosporine for Frequently Relapsing Nephrotic Syndrome in ChildrenClinical Journal of the American Society of Nephrology, 2012
- Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter studyPediatric Nephrology, 2009
- In utero exposure to mycophenolate mofetil: A characteristic phenotype?American Journal of Medical Genetics Part A, 2007
- Management of Steroid-Resistant Focal Segmental Glomerulosclerosis in Children Using TacrolimusAmerican Journal of Nephrology, 2006
- Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosisNephrology Dialysis Transplantation, 2005
- Steroid-sensitive nephrotic syndrome: From childhood to adulthoodAmerican Journal of Kidney Diseases, 2003
- Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndromeKidney International, 2002
- Long term effects of cyclophosphamide on testicular function.BMJ, 1985